Response to Y. Sasaki et al.: Is repeating FOLFIRINOX in the original dosage and treatment schedule tolerable in Japanese patients with pancreatic cancer?
Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo, Japan.
Takuji
T
Okusaka
Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Chiba, Japan.
Masafumi
M
Ikeda
Department of Gastrointestinal Oncology, Shizuoka Cancer Center, Shizuoka, Japan.
Akira
A
Fukutomi
Department of Hepatobiliary and Pancreatic Oncology, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan.
Tatsuya
T
Ioka
Department of Medical Oncology, Kyorin University School of Medicine, Tokyo, Japan.
Junji
J
Furuse
Department of Hepatobiliary and Pancreatic Oncology, Kanagawa Cancer Center, Yokohama City, Kanagawa, Japan.
Shinichi
S
Ohkawa
Department of Gastroenterology, Graduate School of Medicine, the University of Tokyo, Tokyo, Japan.
Hiroyuki
H
Isayama
Department of Clinical Oncology, St. Marianna University School of Medicine, Kanagawa, Japan.
Narikazu
N
Boku
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D010190:Pancreatic Neoplasms / Q000188:drug therapy*